RedHill Biopharma Announces Planned Expansion of Opaganib Global Phase 2/3 COVID-19 Study to the U.S.

Following review of data from the U.S. Phase 2 study by the FDA, RedHill plans to expand the global Phase 2/3 study of orally-administered opaganib for severe COVID-19 to the U.S.
The study has enr… [read more]

Leave a Comment